We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MacroGenics has announced that the National Institute for Allergy and Infectious Diseases (NIAID), part of the U.S. NIH, awarded the company a $50 million contract over five years to develop a monoclonal antibody to the West Nile virus.
Italian
drug-delivery firm Eurand announced that it has entered into a development and license agreement with GlaxoSmithKline (GSK) whereby Eurand will use its Microcaps taste-masking technology and AdvaTab oral disintegration tablet technologies to develop a new formulation of an undisclosed GSK product.
Australia's Therapeutic Goods Administration (TGA) and Canada's Biologics and Genetic Therapies Directorate (BGTD) have announced a joint project, the Parallel Review Project, which aims to enhance cooperation between the regulators.
GTC Biotherapeutics, Inc. and LFB- Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire francais du Fractionnement et des Biotechnologies S.A.) announced that they have entered into a strategic collaboration to develop selected recombinant plasma proteins and monoclonal antibodies using GTC's transgenic production platform.
MedTech Holdings Limited will continue with its acquisition of a Zimbabwe pharmaceutical company which will become a 100 percent owned subsidiary of the company.
Biogen Idec Canada and Elan Corporation announced Wednesday that following a priority review process, Health Canada has granted approval to TYSABRI (natalizumab) for the treatment of relapsing-remitting multiple sclerosis (MS).
Merck Specialities has received marketing approval for Erbitux, its gold standard new-targeted cancer therapy drug, for the treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) cancer.
Cumbre Pharmaceuticals and the Global Alliance for Tuberculosis Drug Development (TB Alliance), a public-private partnership to develop new TB drugs, have announced plans to pursue a joint program to develop new, promising anti-tuberculosis agents that will shorten treatment, be effective against multidrug-resistant strains, treat HIV-TB co-infection and improve treatment of latent infection.